WallStSmart

agilon health Inc (AGL)vsJohnson & Johnson (JNJ)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Johnson & Johnson generates 1554% more annual revenue ($97.93B vs $5.92B). JNJ leads profitability with a 21.5% profit margin vs -3.9%. JNJ earns a higher WallStSmart Score of 59/100 (C).

AGL

Hold

41

out of 100

Grade: D

Growth: 8.7Profit: 2.5Value: 5.0Quality: 6.0
Piotroski: 3/9Altman Z: 1.54

JNJ

Buy

59

out of 100

Grade: C

Growth: 4.7Profit: 8.5Value: 3.3Quality: 5.5
Piotroski: 3/9Altman Z: 2.64
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for AGL.

JNJSignificantly Overvalued (-86.1%)

Margin of Safety

-86.1%

Fair Value

$141.74

Current Price

$255.56

$113.82 premium

UndervaluedFair: $141.74Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AGL2 strengths · Avg: 9.5/10
EPS GrowthGrowth
301.0%10/10

Earnings expanding 301.0% YoY

Debt/EquityHealth
0.159/10

Conservative balance sheet, low leverage

JNJ5 strengths · Avg: 8.8/10
Market CapQuality
$613.99B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
24.8%9/10

Every $100 of equity generates 25 in profit

Profit MarginProfitability
21.5%9/10

Keeps 22 of every $100 in revenue as profit

Operating MarginProfitability
29.2%8/10

Strong operational efficiency at 29.2%

Free Cash FlowQuality
$3.39B8/10

Generating 3.4B in free cash flow

Areas to Watch

AGL4 concerns · Avg: 3.3/10
Altman Z-ScoreHealth
1.544/10

Distress zone — elevated risk

Market CapQuality
$1.43B3/10

Smaller company, higher risk/reward

Operating MarginProfitability
1.3%3/10

Operating margin of 1.3%

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

JNJ4 concerns · Avg: 2.8/10
P/E RatioValuation
29.5x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
2.822/10

Expensive relative to growth rate

EPS GrowthGrowth
-0.9%2/10

Earnings declined 0.9%

Comparative Analysis Report

WallStSmart Research

Bull Case : AGL

The strongest argument for AGL centers on EPS Growth, Debt/Equity.

Bull Case : JNJ

The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.

Bear Case : AGL

The primary concerns for AGL are Altman Z-Score, Market Cap, Operating Margin.

Bear Case : JNJ

The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.

Key Dynamics to Monitor

AGL profiles as a turnaround stock while JNJ is a mature play — different risk/reward profiles.

AGL carries more volatility with a beta of 3.00 — expect wider price swings.

AGL is growing revenue faster at 7.2% — sustainability is the question.

JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.

Bottom Line

JNJ scores higher overall (59/100 vs 41/100), backed by strong 21.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

agilon health Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

agilon health, inc. The company is headquartered in Long Beach, California.

Visit Website →

Johnson & Johnson

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.

Visit Website →

Want to dig deeper into these stocks?